A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Launched by TARGET PHARMASOLUTIONS, INC. · Jun 23, 2016
Trial Information
Current as of May 05, 2025
Recruiting
Keywords
ClinConnect Summary
The TARGET-NASH study is looking at patients who have Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH), which are conditions where fat builds up in the liver without the influence of alcohol. This study will track patients over time to understand how well current and future treatments work and to ensure they are safe. It's an observational study, meaning researchers will gather information from patients as they receive regular care, rather than giving them a specific treatment.
To participate in this study, you need to be at least 2 years old and currently being treated for NAFLD or NASH. The study is open to everyone, regardless of gender. Participants can expect to share their health information with researchers, which will help improve understanding and treatment of liver diseases. It's important to note that individuals who cannot provide consent or assent will not be eligible to join the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults and children (age 2 or older) being managed or treated for nonalcoholic fatty liver disease. Diagnosis is based on the clinical judgement of the care provider.
- Exclusion Criteria:
- • 1. Inability to provide informed assent/consent.
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Ann Arbor, Michigan, United States
Philadelphia, Pennsylvania, United States
Durham, North Carolina, United States
New York, New York, United States
Charleston, South Carolina, United States
Charlottesville, Virginia, United States
Iowa City, Iowa, United States
Chicago, Illinois, United States
Cincinnati, Ohio, United States
Miami, Florida, United States
Omaha, Nebraska, United States
Hartford, Connecticut, United States
Morgantown, West Virginia, United States
Sacramento, California, United States
Gainesville, Florida, United States
Chapel Hill, North Carolina, United States
Louisville, Kentucky, United States
Richmond, Virginia, United States
Baltimore, Maryland, United States
Philadelphia, Pennsylvania, United States
Burlington, Vermont, United States
Indianapolis, Indiana, United States
Houston, Texas, United States
Cincinnati, Ohio, United States
Asheville, North Carolina, United States
Valencia, , Spain
New York, New York, United States
Winston Salem, North Carolina, United States
Berlin, , Germany
Barcelona, , Spain
Palo Alto, California, United States
Skokie, Illinois, United States
Sevilla, , Spain
Columbus, Ohio, United States
Aurora, Colorado, United States
Atlanta, Georgia, United States
Houston, Texas, United States
Oklahoma City, Oklahoma, United States
Shreveport, Louisiana, United States
Aachen, Nrw, Germany
Morehead City, North Carolina, United States
New Brunswick, New Jersey, United States
Tampa, Florida, United States
Washington, District Of Columbia, United States
Santander, Cantabria, Spain
San Jose, California, United States
Pittsburgh, Pennsylvania, United States
Pasadena, California, United States
Live Oak, Texas, United States
Madison, Wisconsin, United States
Cleveland, Ohio, United States
Gainesville, Florida, United States
Richmond, Virginia, United States
Seattle, Washington, United States
New Orleans, Louisiana, United States
Phoenix, Arizona, United States
Hartford, Connecticut, United States
Clearwater, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Palm Harbor, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Houma, Louisiana, United States
Saint Louis, Missouri, United States
Bronx, New York, United States
Manhasset, New York, United States
Charlotte, North Carolina, United States
Greenville, South Carolina, United States
Dallas, Texas, United States
Frankfurt, Hesse, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials